Chromium(III), insoluble salts

CASRN 16065-83-1

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (17 pp, 136 K) last updated: 09/03/1998

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
1.5 None No effects observed NOAEL (ADJ): 1.468 x103
mg/kg-day
100
MF: 10
Low

Reference Concentration for Inhalation Exposure (RfC) (PDF) (17 pp, 136 K) last updated: 09/03/1998
Information reviewed but value not estimated.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (17 pp, 136 K) last updated: 09/03/1998

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (US EPA, 1996)
Basis:
  • Applying the criteria for evaluating the overall weight-of-evidence for carcinogenicity to humans outlined in EPA's guidelines for carcinogen risk assessment (U.S. EPA, 1986), trivalent chromium is most appropriately designated a Group D -- Not classified as to its human carcinogenicity. Using the Proposed Guidelines for Carcinogen Risk Assessment (EPA, 1996), there are inadequate data to determine the potential carcinogenicity of trivalent chromium, as discussed below. However, the classification of hexavalent chromium as a known human carcinogen raises a concern for the carcinogenic potential of trivalent chromium.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (17 pp, 136 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (17 pp, 136 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.